December 2024 Br J Cardiol 2024;31:126–7 doi:10.5837/bjc.2024.051
Ismail Sooltan, Hesham Ismail, Aqib Khan, Sudantha Bulugahapitiya
SGLT2 inhibitors exert their cardioprotective effect through several proposed mechanisms. Primarily, by inhibiting the SGLT2 in the proximal renal tubules, these agents promote urinary glucose excretion, leading to reductions in serum glucose levels, body weight, and blood pressure.1,2 Additionally, SGLT2 inhibitors are thought to drive cardiovascular benefits by promoting natriuresis and diuresis, reducing preload and afterload on the heart.1,2 They also appear to improve myocardial energetics, reduce oxidative stress and inflammation, and exert favourable effects on cardiac remodelling and vascular function.1,2 The DAPA-HF (Dapagliflozin a
March 2003 Br J Cardiol 2003;10:137-40
Omar Ali
No content available
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits